PDS Biotechnology Story

<div class='circular--portrait' style='background:#FF01C9;color: #FFF8DC;font-size:4em;'>PB</div>
PDSB -- USA Stock  

USD 2.38  0.29  10.86%

While many traders today are more concerned about the preservation of capital over market returns, PDS Biotechnology could be one exception. We will evaluate why we are still optimistic in anticipation of a recovery. This post is to show some fundamental factors affecting PDS Biotechnology's products and services. I will also drop some light on how it may impact the investing outlook for the firm in September.
Published over a month ago
View all stories for PDS Biotechnology | View All Stories
Wild options for PDS Biotechnology investors
About 36.0% of PDS Biotechnology outstanding shares are owned by corporate insiders. Insiders ownership of PDS Biotechnology refers to the amount of PDS Biotechnology equity owned by PDS Biotechnology officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of PDS Biotechnology, including its current ownership diagnostics.

How important is PDS Biotechnology's Liquidity

PDS Biotechnology financial leverage refers to using borrowed capital as a funding source to finance PDS Biotechnology ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. PDS Biotechnology financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between PDS Biotechnology's total debt and its cash.

How PDS Biotechnology utilizes its cash?

To perform a cash flow analysis of PDS Biotechnology, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash PDS Biotechnology is receiving and how much cash it distributes out in a given period. The PDS Biotechnology cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Acquisition by Frank BeduAddo of 100000 shares of PDS Biotechnology subject to Rule 16b-3

Legal trades by PDS Biotechnology insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
PDS Biotechnology insider trading alert for grant of employee stock option (right to buy) by Frank BeduAddo, PresidentCEO, on 19th of July 2020. This event was filed by Pds Biotechnology Corp with SEC on 2019-07-01. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down PDS Biotechnology Further

PDS Biotechnology owns a total of fifteen million three hundred sixty thousand outstanding shares. PDS Biotechnology has noticeable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how much assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.

Ownership Breakdown

Retail Investors
Retail Investors59.05

Another small slip for PDS Biotechnology

The information ratio is down to 0.18 as of today. As of the 13th of August 2020, PDS Biotechnology holds the Risk Adjusted Performance of 0.3285, semi deviation of 7.98, and Market Risk Adjusted Performance of (2,197). Concerning fundamental indicators, the technical analysis model allows you to check practical technical drivers of PDS Biotechnology, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We have analyzed nineteen technical drivers for PDS Biotechnology, which can be compared to its competitors. Please check PDS Biotechnology information ratio, value at risk, as well as the relationship between the Value At Risk and expected short fall to decide if PDS Biotechnology is priced more or less accurately, providing market reflects its current price of 2.94 per share. Please also confirm PDS Biotechnology total risk alpha, which is currently at 0.3935 to check out the company can sustain itself at some point in the future.

Whereas some other companies in its industry are either recovering or due for a correction, PDS Biotechnology may not be performing as strong as the other in terms of long-term growth potentials. All things considered, as of the 13th of August 2020, we see that PDS Biotechnology moves indifferently to market moves. The company is undervalued with below average probability of financial unrest within the next 24 months. However, our primary 30 days advice on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of PDS Biotechnology. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com